7749
MEDIKIT CO.,LTD
メディキット株式会社
Healthcare · Medical Instruments & Supplies
Medikit Co.,Ltd., together with its subsidiaries, develops, manufactures, sells, and exports medical devices related to blood vessels and blood in Japan and internationally. The company offers IV catheters, such as Supercath 5 and Supercath Ztu-V; hemodialysis products, including Supercath PRO, Supercath NEO, and Supercath Clampcath; and intervention products comprising Supersheath sheath introducers and Mongoose angiography catheters. It also provides indwelling needles for artificial dialysis; and needles for blood transfusions and infusions. Medikit Co.,Ltd. was founded in 1973 and is headquartered in Bunkyo, Japan.
Read more
← Companies
Overview
Filings & Signals
Ownership
Financials
▾ Collapse Charts
Income Statement
Balance Sheet
Cash Flow
Ratios & Per Share
Metric
FY 2025
TDnet
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Net Sales
¥23.8B
¥22.6B
¥21.9B
¥21.6B
¥20.1B
Cost of Sales
¥14.8B
¥13.9B
¥13.1B
¥13.3B
¥11.9B
Gross Profit
¥9.0B
¥8.7B
¥8.8B
¥8.3B
¥8.2B
SG&A
¥4.7B
¥4.2B
¥4.1B
¥4.2B
¥3.8B
Operating Income
¥4.3B
¥4.5B
¥4.7B
¥4.1B
¥4.4B
Non-Operating Income
¥235M
¥197M
¥196M
¥125M
¥155M
Dividend Income
—
¥17M
¥15M
¥15M
¥16M
Interest Income
—
¥15M
¥4M
¥3M
¥3M
Non-Operating Expenses
—
¥26M
¥92M
¥65M
¥28M
Interest Expense
—
¥8M
¥8M
¥8M
¥7M
Ordinary Income
¥4.5B
¥4.7B
¥4.8B
¥4.2B
¥4.5B
Pre-tax Income
¥4.5B
¥4.7B
¥4.8B
¥4.3B
¥4.5B
Income Taxes
¥1.5B
¥1.6B
¥1.7B
¥1.4B
¥1.5B
Current Tax
—
¥1.6B
¥1.7B
¥1.4B
¥1.0B
Deferred Tax
—
¥90M
¥-14M
¥21M
¥449M
Net Income (owners)
¥3.0B
¥3.0B
¥3.1B
¥2.9B
¥3.0B
Comprehensive Income
—
¥3.1B
¥3.4B
¥3.0B
¥3.0B
EBITDA
¥6.1B
¥6.2B
¥6.2B
¥5.4B
¥5.7B
Goodwill Amort. (J-GAAP)
—
¥217M
¥231M
¥41M
—
EPS
¥206.37
¥204.55
¥187.95
¥170.67
¥178.14
Shares Outstanding
—
14.6M
14.8M
16.8M
16.8M
Shares Issued (total)
—
15.9M
17.9M
18.9M
18.9M
Treasury Shares
—
1.3M
3.1M
2.1M
2.1M
Metric
FY 2025
TDnet
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Total Assets
¥53.3B
¥52.5B
¥51.0B
¥53.2B
¥51.1B
Current Assets
¥33.2B
¥33.2B
¥34.5B
¥38.2B
¥38.5B
Cash & Deposits
¥21.0B
¥21.6B
¥23.6B
¥27.6B
¥28.1B
Trade Receivables
—
¥5.0B
¥5.2B
¥5.6B
¥4.8B
Non-Current Assets
¥20.1B
¥19.2B
¥16.5B
¥15.0B
¥12.5B
PP&E
¥14.9B
¥14.4B
¥11.5B
¥10.4B
¥10.8B
Goodwill
—
¥2.1B
¥2.3B
¥1.9B
—
Intangible Assets
—
¥3.3B
¥3.5B
¥3.1B
¥127M
Investment Securities
¥1.3B
¥779M
¥962M
¥882M
¥928M
Deferred Tax Assets
—
¥260M
¥311M
¥403M
¥420M
Total Liabilities
¥6.5B
¥7.3B
¥6.9B
¥5.9B
¥5.3B
Current Liabilities
¥5.3B
¥6.2B
¥5.7B
¥4.7B
¥4.4B
Accounts Payable
—
¥3.5B
¥3.2B
¥2.5B
¥2.6B
Taxes Payable
—
¥867M
¥898M
¥766M
¥605M
Non-Current Liabilities
¥1.2B
¥1.2B
¥1.2B
¥1.2B
¥871M
Pension Obligations
—
—
—
¥87M
¥85M
Deferred Tax Liab.
—
¥340M
¥336M
¥331M
—
Total Equity
¥46.8B
¥45.2B
¥44.1B
¥47.3B
¥45.8B
Capital Stock
—
¥1.2B
¥1.2B
¥1.2B
¥1.2B
Capital Surplus
—
¥8.4B
¥8.4B
¥10.4B
¥10.4B
Retained Earnings
¥39.0B
¥37.3B
¥39.8B
¥38.5B
¥37.2B
Treasury Stock
—
¥-2.5B
¥-6.0B
¥-3.2B
¥-3.3B
AOCI
—
¥740M
¥674M
¥390M
¥244M
Equity (owners)
¥45.7B
¥44.4B
¥43.5B
¥46.9B
¥45.5B
Net Cash ⓘ
¥21.0B
¥21.6B
¥23.6B
¥27.6B
¥28.1B
NCAV ⓘ
¥26.7B
¥25.9B
¥27.6B
¥32.3B
¥33.3B
NCAV/Share
—
¥1,774
¥1,867
¥1,923
¥1,982
BV/Share
—
¥3,039
¥2,937
¥2,794
¥2,714
Metric
FY 2025
TDnet
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Operating CF
¥4.7B
¥3.6B
¥4.8B
¥4.5B
¥3.2B
Interest Paid
—
¥-8M
¥-8M
¥-7M
¥-7M
Interest Received
—
¥30M
¥19M
¥19M
¥18M
D&A
¥1.8B
¥1.5B
¥1.3B
¥1.3B
¥1.3B
Goodwill Amort.
—
¥217M
¥231M
¥41M
—
Investing CF
¥-1.3B
¥-3.9B
¥3.2B
¥-3.6B
¥-1.7B
CapEx
¥3.4B
¥3.8B
¥1.7B
¥983M
¥1.8B
Purchase Investments
—
¥-6M
¥-6M
¥-10M
¥-6M
Financing CF
¥-1.8B
¥-1.9B
¥-6.6B
¥-1.5B
¥-901M
Dividends Paid
—
¥-1.3B
¥-1.8B
¥-1.5B
¥-835M
Share Buybacks
—
¥-551M
¥-4.8B
—
¥-67M
Free Cash Flow
¥1.3B
¥-256M
¥3.1B
¥3.5B
¥1.4B
Net Change in Cash
—
¥-2.1B
¥1.5B
¥-525M
¥627M
Metric
FY 2025
TDnet
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
ROE
6.5%
6.8%
6.7%
6.2%
6.7%
ROA
5.7%
5.8%
5.9%
5.5%
5.9%
EPS
¥206.37
¥204.55
¥187.95
¥170.67
¥178.14
DPS
¥50.00
¥90.00
¥80.00
¥100.00
¥60.00
BPS
¥3,231.16
¥3,089.58
¥2,982.56
¥2,817.20
¥2,728.04
FCF/Share
—
¥-18
¥213
¥208
¥82
NCAV/Share
—
¥1,774
¥1,867
¥1,923
¥1,982
Payout Ratio
24.2%
44.0%
42.6%
58.6%
33.7%
Event Timeline
S Shareholder
A Capital Signal
▾ Hide Chart
Large Shareholder Reports 16
Date Activist Stake Event Flag Demands Source
2025-08-26
Takashi Nakajima
40.67%
+0.02%
change
Passive
—
2025-07-22
Takashi Nakajima
40.65%
+6.07%
change
Passive
—
2025-03-07
FMR LLC
6.48%
+1.43%
change
Passive
—
2025-03-07
VARECS Partners Limited
14.17%
+1.47%
change
Passive
—
2024-11-07
Takashi Nakajima
34.58%
+0.01%
change
Passive
—
2024-05-22
Takashi Nakajima
34.57%
+3.33%
change
Passive
—
2024-05-22
Hiroko Nakajima
3.02%
change
Passive
—
2024-04-05
FMR LLC
5.05%
+0.42%
initial_5pct
Passive
—
2024-03-06
VARECS Partners Limited
12.7%
+1.09%
change
Passive
—
2024-02-07
FMR LLC
4.63%
change
Passive
—
2024-02-02
Takashi Nakajima
31.24%
-10.6%
change
Passive
—
2024-01-15
Takashi Nakajima
41.84%
+0.01%
change
Passive
—
2024-01-11
VARECS Partners Limited
11.61%
change
Passive
—
2024-01-11
United Managers Japan Inc.
—
exit
Passive
—
2023-05-26
Takashi Nakajima
41.83%
change
Passive
—
2023-05-26
Hiroaki Nakajima
5.85%
change
Passive
—
Capital Allocation Signals 1
Date
Type
Amount
Summary
2026-05-15
16:00
Div Increase
¥723M ¥50.0/sh
+11%
Medikit Corporation announced a year-end dividend of ¥50 per share for fiscal year ending March 31, 2026, an increase fr…
Summary
Medikit Corporation announced a year-end dividend of ¥50 per share for fiscal year ending March 31, 2026, an increase from ¥45 in the prior year (11.1% YoY). The total dividend payout of ¥723 million will bring the full-year dividend to ¥100 per share, reflecting the company's commitment to stable dividend continuation while strengthening corporate fundamentals.
Deadline: 2026-06-26
YoY: +11%
Source (JP)
2026年3月31日を基準日とする剰余金の配当...1株当たり配当金 50円00銭...前期実績 45円00銭...年間の配当は1株当たり100円となる予定です。
Top 10 Shareholders
Ownership DNA
#
Shareholder
Shares (thou.)
% of Total
1
㈱ナカジマコーポレーション
5,341,000
36.54%
2
GOLDMAN,SACHS & CO.REG
GOLDMAN,SACHS & CO.REG (常任代理人 ゴールドマン・サックス証券株式会社)
1,374,080
9.40%
3
NORTHERN TRUST CO.(AVFC) RE FIDELITY FUNDS
NORTHERN TRUST CO.(AVFC) RE FIDELITY FUNDS (常任代理人 香港上海銀行 東京支店)
950,600
6.50%
4
GOLDMAN SACHS INTERNATIONAL
GOLDMAN SACHS INTERNATIONAL (常任代理人 ゴールドマン・サックス証券株式会社)
892,300
6.11%
5
中島 崇
847,200
5.80%
6
一般財団法人中島育英奨学会
600,000
4.11%
7
中島 弘子
535,000
3.66%
8
STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人 株式会社みずほ銀行)
466,308
3.19%
9
栗田 一江
462,000
3.16%
10
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT (常任代理人 香港上海銀行東京支店)
412,700
2.82%
Domestic Nominees
0.0%
+0.0% vs 2024
Trust bank custodians — GPIF, pensions, investment trusts
Foreign Custodians
0.0%
+0.0% vs 2024
Sub-custodians for foreign asset managers
Direct / Strategic
81.3%
+1.5% vs 2024
Named entities with disclosed investment intent
Shareholder
Trend
2023
2024
2025
㈱ナカジマコーポレーション
37.57%
36.07%
36.54%
+0.47%
GOLDMAN,SACHS & CO.REG
GOLDMAN,SACHS & CO.REG
7.47%
9.09%
9.40%
+0.31%
NORTHERN TRUST CO.(AVFC) RE FIDELITY FUNDS
NORTHERN TRUST CO.(AVFC) RE FIDELITY FUNDS
5.90%
5.89%
6.50%
+0.61%
GOLDMAN SACHS INTERNATIONAL
GOLDMAN SACHS INTERNATIONAL
6.03%
6.84%
6.11%
-0.73%
中島 崇
↑
3.34%
3.81%
5.80%
+1.99%
一般財団法人中島育英奨学会
3.57%
4.06%
4.11%
+0.05%
中島 弘子
3.22%
3.65%
3.66%
+0.01%
STATE STREET BANK AND TRUST COMPANY 505001
NEW ENTRY
—
—
—
3.19%
NEW
栗田 一江
NEW ENTRY
—
—
—
3.16%
NEW
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT
—
2.57%
2.82%
+0.25%
SSBTC CLIENT OMNIBUS ACCOUNT
SSBTC CLIENT OMNIBUS ACCOUNT
last seen 2024
Exited Top 10
—
3.99%
—
中島 弘明
last seen 2024
Exited Top 10
9.50%
3.81%
—
NORTHERN TRUST CO.(AVFC)RE NON TREATY CLIENTS ACCOUNT
last seen 2023
Exited Top 10
1.84%
—
—
NORTHERN TRUST CO.(AVFC) RE IEDU UCITS CLIENTS NON LENDING 15 PCT TREATY ACCOUNT
last seen 2023
Exited Top 10
2.20%
—
—
Concentration (HHI)
ⓘ
1671
1547
1595
3 fiscal years · top-10 holders per year · >2,500 HHI = high concentration · entity-resolved